Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transcription activation suppressor family member 2 (TASOR2)
- Target
- TASOR2
- Molecular classification
- Other, Predicted epigenetic regulator, Nuclear protein
01
Overview
Transcription activation suppressor family member 2 (TASOR2/FAM208B) is a large, unstable intracellular protein expressed in various human tissues, primarily located in the cytosol and nucleus. The gene spans chromosome 10p15.1, and the protein features domains of unknown function (DUF3699 and DUF3715), significant serine phosphorylation sites, and a nuclear localization signal. The function is presumed related to negative regulation of gene expression and epigenetic control, suggested by expression patterns and post-translational modifications. FAM208B shows dynamic expression through development, peaking at the blastocyst stage, and is differentially regulated in several cancers and other diseases, where it might serve as a biomarker. Currently, FAM208B/TASOR2 has not been recognized as a classical therapeutic target, and its interaction with drugs or direct mechanism of disease modulation remains to be established[2][4][5][8].
- Other names
- TASOR2FAM208BC10orf18KIAA2006bA318E3.2Family with sequence similarity 208 member BProtein FAM208BTranscription activation suppressor family member 2
02
Biological functions
Negative regulation of gene expressionEpigenetic controlPossible intracellular signaling (based on serine content, phosphorylation)Developmental rolesNo direct experimental evidence for specific molecular or cellular functions
03
Disease associations
Cancer (anal squamous cell carcinoma, follicular lymphoma, colorectal cancer; altered expression in diverse tumors)Infection (downregulated in RSV-infected bronchial cells)Degenerative disease (upregulated in acute macular degeneration)Other (based on differential expression; clinical significance is not fully established)
04
Biomarkers
FAM208B fusion as a possible biomarker in Donor Cell LeukemiaDownregulation as a biosignature for respiratory syncytial virus (RSV) infectionUpregulation as a hub gene in Stage IV colorectal cancer
Beyond the preview
Go deeper on Transcription activation suppressor family member 2 (TASOR2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transcription activation suppressor family member 2 (TASOR2).